FWM
NBIX icon

Focused Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Focused Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40
Closed -$4K – 1001
2021
Q1 		$4K Sell
40
-585
-94% -$61.3K ﹤0.01% 749
2020
Q4 		$60K Buy
+625
New +$60.4K 0.01% 336

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

Focused Wealth Management's NBIX Position: Q2 2021 in Review

Focused Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 40 shares — an estimated $4K sold.

Focused Wealth Management first reported a position in NBIX in Q4 2020 and held it in 2 quarters. The position peaked at $60K in Q4 2020. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Focused Wealth Management reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Focused Wealth Management sold 40 Neurocrine Biosciences shares in Q2 2021, an estimated $4K.
  • Focused Wealth Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 2 quarters.
  • Focused Wealth Management's Neurocrine Biosciences position peaked at $60K in Q4 2020.
  • 408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Focused Wealth Management's 13F filing for Q2 2021, filed 15 Jul 2021.